1. Fibromyalgia syndrome (FMS) is a common chronic widespread pain syndrome mainly affecting women. The aim of this study was to explore the frequency and clinical significance of catechol-O-methyltransferase (COMT) gene Val158Met polymorphism in a large cohort of Turkish patients with FMS. 2. The study included 379 FMS patients and 290 controls. Genomic DNA was isolated and genotyped using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analyses. 3. The genotype frequencies of Val158Met polymorphism showed a small difference between FMS patients and healthy controls (p = 0.047), however, the Met/Met genotype was significantly higher in FMS patients than healthy controls (p = 0.016). No difference was observed for allele frequencies between two groups. Stratification analysis according to clinical features for this disease reveals that weight, FMS Impact Questionnaire score, algometry and Raynaud's syndrome, were detected to have statistically significant associations with Val158Met polymorphism (p = 0.037, p = 0.042, p = 0.039 and p = 0.033, respectively). Pain sensitivity, measured by algometry, was statistically higher in patients with Met/Met genotype than the patients with Val/Val and Val/Met genotypes (p = 0.017). 4. The results of this study suggested that COMT gene Val158Met polymorphism is positively associated with FMS and play a relevant role in the clinical symptoms of the disease.
OBJECTIVES:Fibromyalgia syndrome (FMS) is characterized by complaints of chronic musculoskeletal pain, fatigue, and difficulty in falling asleep. Obstructive sleep apnea syndrome (OSAS) is associated with symptoms, such as morning fatigueness and unrefreshing sleep. We aimed to investigate the presence of OSAS and objectively demonstrate changes in sleep pattern in patients with FMS. MATERIAL AND METHODS:Polysomnographic investigations were performed on 24 patients with FMS. Patients were divided into two groups: patients with and without OSAS (Group 1 and Group 2, respectively). A total of 40 patients without FMS who presented to the sleep disorders polyclinic with an initial diagnosis of OSAS were included in Group 3. Based on their apnea hypopnea index (AHI), OSAS in the patients were categorized as mild (AHI,(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15), moderate (30), or severe (>30). RESULTS:OSAS was detected in 50% of patients with FMS. The most prominent clinical findings were morning fatigue and sleep disorder, which were similar in three groups. In polysomnography (PSG) evaluation, patients with FMS had mild (33%), moderate (25%), and severe (42%) OSAS. In correlation analyses, negative correlations were observed between fibromyalgia impact questionnaire (FIQ) and mean oxygen saturation, visual analogue scale (VAS), and minimum oxygen saturation, whereas a positive correlation was found between FIQ and desaturation times in patients with FMS. CONCLUSION:Detection of OSAS in 50% of the patients with FMS, and similar rates of complaints of sleep disorder and morning fatigue of OSAS and FMS cases are important results. Detection of correlation between the severity of hypoxemia and FIQ and VAS scores are significant because it signifies the contribution of increased tissue hypoxemia to the deterioration of clinical status. Diagnosis and treatment of OSAS associated with FMS are important because of their favorable contributions to the improvement of the clinical picture of FMS. KEYWORDS:Obstructive sleep apnea syndrome, fibromyalgia syndrome, polysomnography, sleep disorders, apnea hypopnea index, hypoxemia INTRODUCTIONFibromyalgia syndrome (FMS) is a chronic health problem that presents with pain all over the body, with other symptoms, such as tenderness of the affected joints, muscles fatigue, sleep problems (waking up unrefreshed and excessive daytime sleepiness), and cognitive impairment [1]. Since its etiology is not fully known, its treatment is symptomatic. Patients with FMS are usually treated with various combinations of physiotherapy, psychotherapy, psychotrophic drugs, and analgesics. Treatment effectiveness in FMS is limited, and these patients frequently lead their lives with symptoms of chronic insomnia, sleep problems, fatigue, and pain [2].Obstructive sleep apnea syndrome (OSAS) is a pathology with systemic effects that are characterized by associated symptoms of recurrent episodes of upper respiratory tract obstruction, hypoxemia, arousals during sleep, morning fatigue because of impaired sleep ...
The aim of this study was to evaluate the effect of the melatonergic M1 and M2 receptor agonist and serotonergic 5-HT2C receptor antagonist agomelatine on the spike wave discharges (SWDs) seen in electrocorticographic (ECoG) recordings of WAG/ Rij rats with absence epilepsy. Twenty-one WAG/Rij male rats were used in this study. Tripolar electrodes were placed on skulls and control ECoG activities were recorded. Experimental groups received normal saline (Group I: 1 mL, intraperitoneally (i.p)), agomelatine (Group II: 40 mg/kg, i.p), and melatonin (Group III: 40 mg/kg, i.p) injections for 7 days. Following this period, 2-h ECoG recordings were repeated. The number of SWDs and their durations were calculated. The total number and duration of SWDs decreased in both the agomelatine and melatonin groups. The systemic administration of agomelatine and melatonin attenuated the genetic absence epilepsy seizures in WAG/Rij rats. The repressive effect of agomelatine on the absence seizures was similar to that of the melatonin used in this study.
Prevalence of restless legs syndrome among psychiatric patients who are under antidepressant or antipsychotic monotherapy Objective: Several groups of medications, such as dopamine blockers, analgesics and antihistaminergics were associated with restless legs syndrome (RLS). Although case reports showed some significant relations, they have many methodological limitations such as co-medications or medical co-morbidities. The aim of this study was to investigate the prevalence and severity of RLS in patients on antidepressant (AD) or antipsychotic (AP) monotherapy.Methods: One hundred and ninety-seven patients and 150 healthy controls were included in the study. RLS was diagnosed according to the International Restless Legs Syndrome Study Group (IRLSSG) criteria. The severity of RLS was evaluated according to IRLSSG rating scale. Participants diagnosed with RLS went under further neurological and psychiatric investigation for excluding secondary causes.Results: One hundred and twenty patients (60.9%) were on AD therapy, while 77 patients (39.1%) were on AP monotherapy. Thirty-two patients (16.2%) and seven controls (4.7%) were diagnosed with RLS according to IRLSSG criteria. The most frequent cause of RLS was quetiapine (28.5%) in the antipsychotic group and paroxetine (22.2%) in the antidepressant group. There was no statistically significant correlation between drug usage duration and RLS severity. Conclusion:AD or AP induced RLS is a common condition. ADs and APs should be considered as a cause for RLS when assesing RLS in psychiatric patients who are under treatment either of these medications.
PurposeIn this study, we investigated overactive bladder (OAB) functions in male patients who used antidepressant drugs (ADs) that were previously examined in female patients, based on conflicting data in literature regarding the effects of AD on OAB and the differences between male and female urinary system physiologies (anatomical and hormonal).MethodsThe study included 202 male patients (a control group of 90 healthy subjects, and an experimental group of 112 patients taking ADs for different disorders). All the patients completed the overactive bladder-validated 8 (OAB-V8) questionnaire, the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and the Beck Depression Inventory (BDS).ResultsThe OAB-V8, ICIQ-SF, and BDS scores for the antidepressant users were significantly higher than those of the control group. The highest prevalence of OAB symptoms was observed in patients taking venlafaxine (68.2%), and the lowest prevalence was in patients taking sertraline (28.0%). Moreover, the frequency of OAB between the antidepressant groups was statistically significant. The univariate logistic regression analyses showed a significant relationship between the presence of OAB, antidepressant usage, BDS score, and the age of a patient. In the multivariate logistic regression analyses, the association between the presence of OAB and antidepressant usage was statistically significant.ConclusionsThe present study showed that the incidence of OAB and the severity of OAB symptoms increased in males using antidepressants for various disorders. This may have been due to unique pharmacological effects, on a molecular or individual level, of serotonin-norepinephrine reuptake inhibitors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.